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In rat liver epithelial cell lines (WB or GN4), angioten-
sin II (Ang II) stimulates cytosolic tyrosine kinase activ-
ity, in part, through a calcium-dependent mechanism. In
other cell types, selected hormones that activate Gi- or
Gq-coupled receptors stimulate the soluble tyrosine ki-
nase, p125FAK. Immunoprecipitation of p125FAK from
Ang II-activated GN4 cells demonstrated a doubling of
p125FAK kinase activity. However, an additional Ang II-
activated tyrosine kinase (or kinases) representing the
majority of the total activity was detected when the
remaining cell lysate, immunodepleted of p125FAK, was
reimmunoprecipitated with an anti-phosphotyrosine
antibody. Cytochalasin D pretreatment blocks G-pro-
tein receptor-dependent tyrosine phosphorylation in
Swiss 3T3 cells. While cytochalasin D decreased the
Tyr(P) content of 65–75-kDa substrates in Ang II-treated
GN4 cells, it did not diminish tyrosine phosphorylation
of 115–130-kDa substrates, again suggesting activation
of at least two tyrosine kinase pathways in GN4 cells. To
search for additional Ang II-activated enzymes, we used
molecular techniques to identify 20 tyrosine kinase se-
quences in these cell lines. None was the major cytosolic
enzyme activated by Ang II. Specifically, JAK2, which
had been shown by others to be stimulated by Ang II in
smooth muscle cells, was not activated by Ang II in GN4
cells. Finally, we purified Tyr(P)-containing tyrosine ki-
nases from Ang II-treated cells, using anti-Tyr(P) and
ATP affinity resins; 80% of the tyrosine kinase activity
migrated as a single 115–120-kDa tyrosine-phosphoryl-
ated protein immunologically distinct from p125FAK. In
summary, Ang II activates at least two separate tyrosine
kinases in rat liver epithelial cells; p125FAK and a pre-
sumably novel, cytosolic 115–120-kDa protein referred
to as the calcium-dependent tyrosine kinase.
In analyzing EGF1-dependent tyrosine phosphorylation in
rat liver epithelial cell, two waves of Tyr(P) substrate phospho-
rylation occurring at 5 and 60 s were noted (1). The latter group
appeared to be phosphorylated in part due to activation of a
second process (e.g. a downstream tyrosine kinase) (2). Subse-
quently, we identified several of the same substrates in Ang II,
vasopressin, or epinephrine-treated cells, and determined that
these G-protein-coupled receptors stimulated tyrosine phos-
phorylation in a calcium-dependent, protein kinase C-inde-
pendent manner (2–4). Since virtually all tyrosine kinases
autophosphorylate on tyrosine residues, immune complex ty-
rosine kinase activity could be assessed in anti-Tyr(P) immu-
noprecipitates from control and Ang II-treated cells. Ang II
increased tyrosine kinase activity within 15–30 s; maximal
activation was seen within 1 to 2 min. Activation was abro-
gated by intracellular chelators that blunt the Ang II-induced
calcium signal (3). The mechanism by which calcium increases
tyrosine kinase activity remains unclear, but the schema is
presumably indirect because tyrosine kinase activity can not be
stimulated by adding calcium to cell-free extracts of these cells.
Thus, our previous work showed that G-protein-coupled recep-
tors generating a calcium signal rapidly, but indirectly, acti-
vate one or more tyrosine kinase(s) (2–4).
Other hormones activating G-protein-coupled receptors also
increase tyrosine phosphorylation (e.g. bombesin (5, 6), brady-
kinin (7), thrombin (8–10), carbachol (11), endothelin (5, 6),
cholecystokinin (12), lysophosphatidic acid (13), and fMet-Leu-
Phe (14)), and our demonstration of Ang II- and vasopressin-
dependent tyrosine phosphorylation has been confirmed by
several groups (15–20). While many of these hormone receptors
(like Ang II) activate Gq-proteins increasing phospholipase C
activity and intracellular calcium (21), several activate Gi-
coupled receptors, which would not be expected to raise intra-
cellular calcium (22). Whatever the mechanism, several inves-
tigators established that stimulation of Gi- or Gq-coupled
receptors activated a 125-kDa tyrosine kinase. This kinase,
p125FAK, localizes to focal adhesions (23–25) and had been
cloned as a substrate of p60v-src (26, 27). In concurrent work,
several laboratories, including our own, showed that signaling
via integrins also stimulated p125FAK phosphorylation and
activity (28–31). This analogy between G-protein stimulation
and cell surface perturbation is extended by the fact that both
integrin (32) and hormone stimulation (see below) activate
MAP kinase.
Many of the hormones noted above that activate tyrosine
phosphorylation also stimulate cell proliferation and the imme-
diate-early gene expression that accompanies growth factor
action. The latter is likely to occur by activation of the MAP
kinase (ERK 1 and ERK 2) pathway (33, 34), or the newly
characterized c-Jun N-terminal kinase (JNK) pathway (35). In
fact, both Gq-coupled receptors (in some instances via a calci-
um-dependent mechanism) and Gi-coupled receptors have been
shown to activate MAP kinase (15, 16, 20, 36–39). In addition,
our laboratory has shown recently that Ang II treatment of rat
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liver epithelial cells produces a 200-fold activation of JNK
through a calcium- and tyrosine kinase-dependent process.2 In
summary, data from several cell types suggest that the selected
Gq- and Gi-coupled receptors as well as other agonists (e.g.
integrin stimulation) can activate p125FAK, MAPK, and JNK.
The potential stimulation of several pathways thought to be
controlled by tyrosine phosphorylation led us to ask whether
Ang II stimulated p125FAK or another tyrosine kinase(s) or
both.
We report that Ang II stimulates at least two cytosolic tyro-
sine kinases. The first, pp125FAK, is tyrosine-phosphorylated
and activated in these cells in an Ang II-dependent manner;
however, greater than 80% of the tyrosine kinase activity re-
sides in another molecule that can be distinguished from
p125FAK. Molecular means were used to identify 20 tyrosine
kinases in the cells, but none appear to be the calcium-depend-
ent cytosolic tyrosine kinase. In contrast, we have partially
purified an autophosphorylating kinase from Ang II-treated
cells by sequential affinity chromatography. This activity mi-
grates as a 115–120-kDa Tyr(P) protein that can be separated
electrophoretically and distinguished from pp125FAK. The pos-
sibility is raised that distinct Ang II-dependent intracellular
signaling pathways are activated through separate tyrosine
kinases.
EXPERIMENTAL PROCEDURES
Materials—EGF was purified from mouse salivary glands as de-
scribed previously (40). Human Ang II (Asp-Arg-Val-Tyr-Ile-His-Pro-
Phe) was obtained from Sigma. Ang II was prepared in 50 mM acetic
acid. EGF was prepared as 100-fold-concentrated solutions in 10 mM
NaPi (pH 7.4), 150 mM NaCl containing 0.1% bovine serum albumin.
Cytochalasin D (Calbiochem) was prepared as stock solutions in di-
methyl sulfoxide (final concentration # 0.1%, v/v). Anti-p125FAK, mono-
clonal antibody 2A7, and polyclonal antibody BC-2 were generously
provided by Tom Parson, University of Virginia. Antibodies to JAK1,
JAK2, and JAK3 were generously provided by Dr. James Ihle, St.
Jude’s. Monoclonal anti-Tyr(P) antibody, PT66, and PT66-agarose were
purchased from Sigma.
Cell Cultures—WB and GN4 cell were maintained at 37 °C in
Richter’s improved minimal essential medium containing 10% fetal
bovine serum and 0.1 mM insulin in a humidified 5% CO2 atmosphere as
described previously (3). Seven to 10 days before each experiment, WB
cells of passages 19–26 or GN4 cell passages 5–15 were seeded onto
plastic culture dishes (Costar) and used when they reached confluence.
Anti-Tyr(P) Immunoblotting—Cell treatments and anti-Tyr(P) im-
munoblotting were performed essentially as described previously (2).
Cell lysates of WB or GN4 cells grown in 35-mm diameter culture
dishes, subcellular fractions, PT66 immunoprecipitates, or affinity
resin fractions were probed in a similar fashion. Briefly, in some exper-
iments treatment incubations were terminated by rapid aspiration of
the medium and addition of 250 ml of ice-cold RIPA buffer. Cell extracts
were scraped from culture dishes and solubilized by addition of 125 ml
of 3-fold-concentrated sodium dodecyl sulfate (SDS)-polyacrylamide gel
electophoresis (PAGE) sample buffer and heating to 100 °C for 3 min.
For experiments in which homogenate, cytosol, and membrane frac-
tions were separated, four 60-mm plates preincubated with 200 mM
vanadate for 15 min and were then treated with vehicle or Ang II for 1
min. Cells were scraped into vanadate-containing immunoprecipitation
buffer (see below) and homogenized in a 2-ml Teflon glass homogenizer
with motor driven pestle on ice (30 strokes). One-ml aliquots were
ultracentrifuged in a Beckman TL100 centrifuge at 105,000 3 g for 45
min. Proteins from cell lysates, subcellular fraction, or affinity proce-
dures were separated by electrophoresis on 7, 8, or 10% polyacrylamide
gels and transferred to nitrocellulose membranes. Blots were probed by
sequential incubation with anti-Tyr(P) antibodies and 125I-protein A
(2–10 mCi/mg; DuPont NEN) or using ECL reagent. Molecular weights
were estimated by using prestained standards (Sigma).
Anti-Tyr(P), p125FAK, JAK, and EGF Receptor Immunoprecipita-
tion—Confluent cultures of WB or GN4 cells in 60-mm dishes, subcel-
lular fractions or affinity column fractions, were immunoprecipitated in
ice-cold lysis buffer, referred to as NLB (20 mM HEPES (pH 7.3) con-
taining 500 mM NaCl, 50 mM NaF, 5 mM EDTA, 1 mM Na3VO4, 1%
Triton X-100, 10% (v/v) glycerol, and 20 mg/ml phenylmethylsulfonyl
fluoride, 10 mg/ml leupeptin, and 100 kallikrein inhibitor units of apro-
tinin per ml). Lysates were clarified prior to immunoprecipitation by
centrifugation at 14,000 3 g for 10 min at 4 °C. Tyrosine-phosphoryl-
ated proteins were precipitated by incubation with monoclonal anti-
Tyr(P) antibody PT66, 5 mg of rabbit anti-mouse IgG, and 10 ml of
Pansorbin (Calbiochem), or 25 ml of protein A/G-agarose (Santa Cruz),
for 2 h at 4 °C. Immune complexes were collected by centrifugation at
14,000 3 g for 3 min at 4 °C, were washed twice with this lysis buffer,
and if used for immune complex tyrosine kinase activity, the precipi-
tates were washed twice with 2-fold concentrated tyrosine kinase assay
buffer (100 mM sodium HEPES (pH 7.6), 60 mMMgCl2, 2 mMMnCl2, 0.2
mM Na3VO4, 0.2% Nonidet P-40), and then were resuspended with 70 ml
of this buffer. In some experiments, an aliquot (10–20 ml) of the washed
immune complex was removed for anti-Tyr(P) immunoblotting after
SDS-PAGE on 8% gels as described. Efficient anti-Tyr(P) recovery of
tyrosine phosphoproteins and kinase activity required high NaCl con-
centration (500 mM) in the cell lysis buffer. We postulate that Tyr(P)
residues are dissociated from endogenous binding domains (e.g. Src
homology domains) at high ionic strength and thereby are made acces-
sible for immunoprecipitation. In cell lysates or affinity fractions,
p125FAK was precipitated using 2–10 ml of monoclonal 2A7; EGF recep-
tor was precipitated with anti-rat polyclonal EGF receptor antibody
1382 prepared in this laboratory. JAKs 1, 2, and 3 were immuno-
precipitated after lysis in NLB with specific antisera provided by
James Ihle.
Immune Complex Tyrosine Kinase Assay and In Vitro Autophospho-
rylation Reactions—Routinely, 10–20-ml aliquots of immune complex
suspension were preincubated for 5 min at 4 °C with 160 mg of the
synthetic tyrosine kinase substrate poly(Glu80-Tyr20) or the control
substrate poly(Glu) (Sigma). Reactions (80 ml total reaction volume)
were initiated by addition of 5 mM [g-32P]ATP (2–10 mCi/reaction) for
cell lysate experiments. Affinity fractions were assayed with 60 mM
ATP, 5–20 mCi of [g-32P]ATP to equalize the ATP concentration in
various fractions. After 4–10 min at 25 °C, 50 ml of the reaction mix was
spotted onto Whatman No. 3MM paper. The papers were washed with
trichloroacetic acid, air-dried, and assayed by liquid scintillation for
acid-insoluble 32P. Tyrosine kinase activity was defined as 32P incorpo-
ration in counts/min occurring in the presence of poly(Glu80-Tyr20)
minus that occurring in the presence of poly(Glu80-Tyr20). This defined
phosphorylation above the background of endogenous protein phospho-
rylation. The rates of tyrosine phosphorylation so measured were linear
for at least 15 min and were proportional to the amount of cell lysate
used for immunoprecipitation. In experiments in which endogenous
substrate autophosphorylation was assessed, the poly(Glu80-Tyr20) was
not added to the reaction mixture. The reactions were terminated at
4–10 min by boiling in SDS-sample buffer. Samples were subjected to
7–8% SDS-PAGE; gels were stained, destained, dried, and subjected to
autoradiography on Kodak AR film. In some instances gels were trans-
ferred to Immobilon and subjected to two dimensional phosphoamino
acid analysis as described previously (2).
Degenerate PCR Cloning of Tyrosine Kinase Domains—Unknown
tyrosine kinase domains were amplified with degenerate oligonucleo-
tides designated TK forward (cca gtt ctc gag cat cgn gat ttn gcn gcn cg)
and TK reverse (ctg can acc tgg atg ccn ta tag cta ttg acc), encoding the
conserved sequences HRDLAAR and DVWSFGV, respectively, as de-
scribed (41). The first strand cDNA template was prepared from poly(A)
mRNA made by cesium chloride isolation of total RNA from the WB cell
line followed by oligo(dT) selection. The cDNA was synthesized using
Moloney murine leukemia virus reverse transcriptase in RT buffer (50
mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM dithiothreitol, and 3 mM
MgCl2), 15 units of RNA guard (Pharmacia Biotech Inc.), 10 pmol of
random hexamers, and 1.25 mM each dNTP in a 20-ml reaction. The
volume of the cDNA was adjusted to 25–60 ml with TE following first
strand synthesis. PCR amplifications were carried out with 5 ml of
random-primed first strand cDNA in a 50-ml reaction volume of PCR
buffer (10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01%
gelatin, and 0.1% Triton X-100), 0.2 mM of each dNTP, 50 pmol of each
primer, and 2.5 units of Taq DNA polymerase (Life Technologies, Inc.)
under the following conditions: 5 min at 94 °C, 1 min at 55 °C, and 2
min at 72 °C (1 cycle), 1 min at 94 °C, 1 min at 55 °C, and 2 min at 72 °C
(22 cycles), and 1 min at 94 °C, 1 min at 55 °C, and 10 min at 72 °C (1
cycle). The PCR product was then gel-purified, cut with XhoI and ClaI
at sites included in the PCR primers, and subcloned into pBSII SK1
(Stratagene). In later experiments, the PCR product was TA-cloned
(Invitrogen) as per manufacturer’s instructions. The 190 cloned PCR
products were sequenced by dideoxy termination sequencing (Seque-2 I. Zohn, H. Yo, X. Li, A. Cox, and H. S. Earp, unpublished results.
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nase 2.0, U. S. Biochemical Corp.), grouped into families (40 of 190 were
Abl), and the sequences compared to the GenBank data base with the
Blast algorithm.
Expression Cloning of WB Cell Tyrosine Kinases—A cDNA library
was constructed in lgt11 using oligo(dT)-primed poly(A)-containing
RNA purified from confluent cultures of WB cells. Recombinants were
screened for cDNAs encoding active tyrosine kinases by a modification
of the method of Letwin et al. (42). A total of 480,000 plaque-forming
units from the unamplified phage library was used to infect Escherichia
coli strain Y1090. Infected cells were plated in LB top agarose on 10
150-mm LB agar plates and incubated for 3 h at 42 °C. When plaques
had become visible, expression of insert sequences was induced by
applying nitrocellulose filters, prewet with 10 mM IPTG, to the surface
of the agarose and continuing incubation at 37 °C. After 4 h, filters were
rinsed briefly with 50 mM Tris-Cl, 150 mM NaCl (pH 7.5), plus 0.05%
sodium azide (“RB”) and blocked overnight in RB containing 3% bovine
serum albumin (Boehringer Mannheim). Plaques containing proteins
phosphorylated on tyrosine were identified by immunoblotting the fil-
ters with purified polyclonal anti-phosphotyrosine antibodies followed
by 125I-protein A as described. Twenty positive plaques were detected.
Phage from the 12 plaques giving rise to the strongest isopropyl-1-thio-
b-D-galactopyranoside induction and anti-phosphotyrosine immuno-
blotting, yielding 8 purified clones with Lambdasorb reagent (Pro-
mega). Insert DNAs were excised by restriction and endonuclease
digestion with EcoRI and ligated into EcoRI-cut pBluescript II(KS1)
(Stratagene). Partial nucleotide sequences of insert cDNAs, obtained
using the Sequenase 2.0 kit (U. S. Biochemical Corp.), were compared to
known sequences using the GCG analysis package.
Affinity Purification—In a typical preparation, 50 150-mm tissue
culture plates of confluent GN4 cells were treated with 1 mM Ang II for
1 min and scraped into 1.0 ml of NLB/plate. After centrifugation, the
lysate was tumbled with 1 ml of PT66-agarose, washed five times, and
eluted with 10 ml of NLB with 10 mM phenylphosphate. The Tyr(P)
elute was brought to 50 mM MgCl2 in 150 mM NaCl and incubated with
0.5 ml of ATP-Sepharose synthesized by one of us (L. Graves). Briefly,
4-aminoanilido-ATP was synthesized by reacting ATP with N-ethyl-N9-
(3-dimethyllaminopropyl)carbodiimide and phenylenediamine. The
product, isolated by high performance liquid chromatography, was an-
alyzed by mass spectrometry to confirm the identity. The 4-aminoani-
lido-ATP derivative was coupled by carbodiimide chemistry to Sepha-
rose resin containing a carboxyl group attached to a 6-carbon linker
(Pharmacia ECH Sepharose). After transfer to a Bio-Rad 1-ml column,
the resin was washed with 150 mM and 500 mM NaCl containing buffers
and the purified ATP-binding proteins were eluted with 1 mM ATP in
six to eight 1-ml fractions. Fractions were combined and used for im-
munoprecipitation (2 h at 0 °C, as described) with p125FAK or EGF
receptor antibodies or were concentrated by incubation with PT66-
agarose overnight at 0 °C. Some aliquots were autophosphorylated in
immune complex kinase assays, as described, and subjected to gel
electrophoresis and autoradiography. Alternatively, aliquots were pre-
pared for mini-gel electrophoresis, followed by silver staining, or after
transfer to nitrocellulose, for Tyr(P) immunoblotting. For some gel
electrophoresis analyses, the bisacrylamide concentration was reduced
from 1 to 0.5% to increase the separation in the 120-kDa region.
RESULTS
The Ang II-dependent Tyr(P) Substrates and Tyrosine Ki-
nase(s) Are Cytosolic Proteins—The subcellular localization of
Ang II-dependent Tyr(P) substrates and tyrosine kinase activ-
ity was investigated in WB and rat liver epithelial cells. Pre-
vious experiments had assessed the time course of substrate
phosphorylation and kinase activity in extracts of cells lysed in
detergent-containing buffers with 500 mM NaCl, protease, and
phosphatase inhibitors (2). To determine subcellular localiza-
tion, cells preincubated with 200 mM vanadate to preinhibit
cellular Tyr(P) phosphatases were incubated with Ang II for 1
min, the time of maximal tyrosine kinase activation. Preincu-
bation with vanadate prolonged the Ang II-dependent tyrosine
phosphorylation response, but did not detectably alter the sub-
strates phosphorylated. Cells were scraped, homogenized on
ice, and centrifugated at 105,000 3 g for 45 min. After resus-
pension of the pelleted membranes, Triton X-100 was added to
a portion of the original homogenate (kept on ice during sub-
cellular fractionation), as well as to the cytosol and membrane
fractions. Following electrophoresis of the samples and transfer
to nitrocellulose, an anti-Tyr(P) immunoblot was performed
(Fig. 1). The majority of the Tyr(P) substrates in Ang II-treated
WB cells were localized to the cytosolic fraction. In contrast,
EGF-stimulated tyrosine phosphorylation of substrates both in
the cytosolic and membrane fractions; the major substrate in
the membrane fraction was the 170-kDa EGF receptor.
To determine the localization of the tyrosine kinase(s) acti-
vated in Ang II-treated cells, the experiment was repeated
using GN4 cells, a chemically transformed line derived from
WB, that expresses ;3-fold more Ang II-stimulated tyrosine
kinase activity. After separating homogenate, cytosol, and
membrane fractions, detergent was added, followed by immu-
noprecipitation with anti-phosphotyrosine monoclonal anti-
body PT66. Immune complex tyrosine kinase activity was per-
formed as described under “Experimental Procedures”
assessing the transfer of 32P from [g-32P]ATP to the exogenous
substrate poly(Glu80-Tyr20). In immunoprecipitates from the
homogenate fraction, Ang II treatment increased tyrosine ki-
nase activity by ;2.5-fold (2,637 cpm for control to 6,199 cpm
for Ang II-treated). At least 75–80% of this activity was found
in the immunoprecipitates of cytosolic Tyr(P) proteins (740 cpm
for control, 4,596 cpm for Ang II-treated). In contrast, little
activity was found in the immunoprecipitates from the mem-
brane fraction (699 cpm for control, 313 cpm for Ang II-treat-
ed). Thus, the majority of the Tyr(P) substrates and virtually
all of the increased tyrosine kinase activity were found in the
cytosolic fraction.
p125FAK Is Activated in Ang II-treated Cells, but Is Not the
Major Ang II-dependent Tyrosine Kinase—The fact that the
Ang II-dependent tyrosine kinase activity was soluble and that
there were Tyr(P) substrates in the p115–130-kDa region led
us to test whether p125FAK was the major kinase activated.
GN4 cells treated with vehicle or Ang II for 1 min were sub-
jected to single or sequential immunoprecipitation protocols
using control mouse Ig (mIg), the anti-Tyr(P) monoclonal anti-
body PT66, or the FAK monoclonal antibody 2A7. Immunopre-
cipitates from treated cells were subjected to electrophoresis,
transfer to nitrocellulose, and Tyr(P) immunoblotting with
PT66 as described under “Experimental Procedures” (Fig. 2).
Immunoprecipitation with irrelevant mIg did not precipitate
Tyr(P)-containing proteins from either control or Ang II-
FIG. 1. Subcellular fractionation of WB cell phosphotyrosine
substrates.WB cells were treated with EGF (1 mg/ml) or Ang II (1 mM)
for 1 min and homogenized in buffers described under “Experimental
Procedures.” Following ultracentrifugation at 105,000 3 g for 45 min,
the particulate fraction was resuspended in an equivalent volume of
buffer and each fraction (homogenate, cytosol, and membrane) was
boiled in SDS sample buffer. Following SDS-PAGE and transfer to
nitrocellulose a phosphotyrosine immunoblot was performed, as under
“Experimental Procedures.” Ang II-dependent Tyr(P) substrates were
found predominantly in the cytosolic fraction.
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treated cells. Immunoprecipitation of p125FAK (Fig. 2, lanes 3
and 6) demonstrated tyrosine phosphorylated p125FAK in con-
trol GN4 cells; Ang II slightly increased p125FAK Tyr(P) con-
tent at 1 min, the time of maximal Ang II-dependent tyrosine
phosphorylation. However, FAK was not the major component
in Ang II-treated cells. Immunoprecipitation with anti-Tyr(P)
PT66 showed the previously described large increase in Tyr(P)
substrates after Ang II treatment (Fig. 2, lanes 2 and 5). To
determine more precisely the portion of Tyr(P) phosphoprotein
in the p120–125 region that was pp125FAK, a sequential im-
munoprecipitation was performed. The first immunoprecipita-
tion with either irrelevant mIg or 2A7 anti-FAK was performed
at 0 °C in vanadate-containing buffers. The supernatants re-
maining from the first immunoprecipitation were then reim-
munoprecipitated with PT66. Preclearance of nearly all immu-
noreactive FAK by 2A7 had little effect on the amount of PT66
immunoprecipitable Tyr(P) substrate from Ang II-treated cells
(Fig. 2, lanes 10 and 11).
While the above indicated that p125FAK is only a small
fraction of the Tyr(P) substrate, it did not determine whether
p125FAK was the major autophosphorylating kinase in immune
complexes. Tyrosine kinase activity assays were performed on
2A7 (p125FAK monoclonal) and PT66 (anti-Tyr(P) antibody)
immunoprecipitates. In five experiments, the immune complex
p125FAK activity measured by the ability of p125FAK immuno-
precipitates to phosphorylate poly(Glu80-Tyr20) nearly doubled
when isolated from cells after Ang II treatment (1 min), from
an average of 6,747 cpm for control to 11,730 cpm for Ang II.
The immune complex tyrosine kinase activity of the PT66 im-
munoprecipitate paired with a representative p125FAK experi-
ment rose from a control of 15,656 cpm to 66,342 cpm after Ang
II treatment (1 min). Autophosphorylation activity was also
assessed by repeating the single and sequential immunopre-
cipitation protocol in control or Ang II-treated GN4 cells and
assessing incorporation from [g-32P]ATP into precipitated pro-
tein in vitro, followed by gel electrophoresis and autoradiogra-
phy of dried gels as described under “Experimental Proce-
dures.” Fig. 3 demonstrates that p125FAK autokinase activity
in 2A7 immunoprecipitates is slightly elevated (lanes 3 and 6)
in Ang II-treated cells (1 min), corresponding to the increase in
immune complex poly(Glu80-Tyr20) activity noted above. Ang
II-dependent PT66 immune complex auto kinase activity was
much greater (Fig. 3, lanes 2 and 5). In the sequential protocol,
immunoprecipitation removing nearly all immunoreactive
p125FAK from the supernatant did little to diminish the subse-
quent PT66-immunoprecipitable autokinase activity seen in
the 115–125-kDa region (Fig. 3, lanes 10 and 11). Examination
of lanes 5, 10, and 11 in Fig. 3 revealed a diffuse band above 120
kDa of phosphorylated protein and one sharp band of in vitro
phosphorylated protein at ;115–120 kDa. On shorter expo-
sures of the autoradiograph, this single band is even more
prominent. This is observed either before (lane 10) or after
(lane 11) the removal of p125FAK by immunoprecipitation, sug-
gesting that a major autophosphorylation protein was not re-
moved by p125FAK antibody. 32P-Phosphoamino acid analysis
by two dimensional thin layer chromatography has shown that
all [32P]phosphate added in vitrowas on tyrosine residues (data
not shown). This analysis suggested that an autophosphorylat-
ing kinase at 115–120 kDa may be the most prominent in vitro
labeled protein, a supposition substantiated by the purification
discussed below.
In studies of p125FAK activation via G-protein-coupled recep-
tors, others tested whether the cytoskeletal was involved in the
signal transduction pathway (19, 24). Preincubation of cells
with cytochalasin D, an agent that disrupts actin microfila-
ments and cytoskeletal movement, prevented the tyrosine
phosphorylation by G-protein-coupled receptor agonists (e.g.
bombesin) in Swiss 3T3 cells (19, 24). GN4 cells were preincu-
bated with 2 mM cytochalasin D for 2 h prior to stimulation with
Ang II (1 min). Fig. 4 demonstrates that cytochalasin D had
little or no effect on Ang II-dependent tyrosine phosphorylation
of substrates in the 115–130-kDa region. We did not assess
p125FAK tyrosine phosphorylation in this experiment, but Fig.
2 demonstrated that depletion of Tyr(P) p125FAK from the
115–130-kDa substrates region would not alter the Tyr(P) im-
munoblotting pattern in Ang II-treated cells. Cytochalasin D
FIG. 2. Phosphotyrosine immunoblot of immunoprecipitated
proteins following Ang II treatment. Rat liver epithelial (GN4) cells
were treated with Ang II and lysed as under “Experimental Proce-
dures.” Samples were then immunoprecipitated with normal mouse IgG
(mIg), anti-phosphotyrosine monoclonal PT66 (p-tyr), or anti-p125FAK
(FAK) antibodies as indicated, boiled in SDS sample buffer, subjected to
SDS-PAGE, and immunoblotted for phosphotyrosine (PT66). Data in
the single immunoprecipitation (left panel) indicate that Ang II stimu-
lates p125FAK tyrosine phosphorylation, but that PT66 immunoprecipi-
tations contain substantially more Tyr(P) substrate. In the double im-
munoprecipitation (right panel), the supernatants of the first
immunoprecipitation were reimmunoprecipitated with PT66 or FAK
antibody as labeled, showing the lack of depletion of phosphotyrosine-
containing proteins following the immunodepletion of FAK.
FIG. 3. Autophosphorylation of immunoprecipitated GN4 cell
Tyr(P) substrates. Rat liver epithelial (GN4) cells were treated with
Ang II (1 min) and lysed as under “Experimental Procedures.” Samples
were then immunoprecipitated with normal mouse IgG (mIg), anti-
phosphotyrosine PT66 (p-tyr), or anti-p125FAK (FAK) antibodies as in-
dicated. Immune complexes were incubated with [g-32P]ATP in phos-
phorylation buffer as described under “Experimental Procedures.”
Following a 2-min incubation the samples were boiled in SDS sample
buffer, subjected to SDS-PAGE, and autoradiographed. The data in the
single immunoprecipitation (left panel) indicate that Ang II stimulates
p125FAK autophosphorylation, but that the Tyr(P) immune complexes
exhibit much greater total autokinase activity. In the double immuno-
precipitation (right panel), the supernatants of the first immunoprecipi-
tation were reimmunoprecipitated as labeled, showing the lack of de-
pletion of tyrosine kinase activity following immunodepletion of FAK,
suggesting the presence of other activated, tyrosine-phosphorylated,
tyrosine kinases after Ang II treatment.
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pretreatment did, however, distinctly inhibit tyrosine phospho-
rylation of 65–75-kDa substrates in Ang II-treated GN4 cells.
In other cell types, Tyr(P) substrates in this region have proved
to be the cytoskeletal protein paxillin, which is tyrosine-phos-
phorylated in cells stimulated by hormones binding to G-pro-
tein-coupled receptors (24). In conclusion, Ang II stimulates
rapid tyrosine phosphorylation of two groups of substrates: one
sensitive and one insensitive to cytochalasin D. This may occur
because Ang II activates at least two tyrosine kinase pathways.
Attempts to Identify an Ang II-regulated Tyrosine Kinase
Other than p125FAK—Molecular technologies and available an-
tibodies were used to identify the range of tyrosine kinases
present in WB rat liver epithelial cells. First, a cDNA library
that had been constructed using WB cell poly(A) mRNA was
used for cDNA expression cloning to identify novel tyrosine
kinases that might not have canonical kinase domain se-
quences but would be detected if expressed in E. coli, which
have neither tyrosine kinases nor tyrosine phosphatases. Anti-
Tyr(P) cDNA expression cloning identified three tyrosine ki-
nases (Fer, Fyn, Bek). Failing to identify a novel cytosolic
tyrosine kinase, degenerative PCR cloning using the tyrosine
kinase domain primers was performed (41, 43). A total of 20
tyrosine kinases were identified in WB cells, including the EGF
receptor and Src (identified using antibodies), the three kinases
noted above detected by expression cloning, and 15 more iden-
tified by PCR. The latter group included three that were novel
when detected (JAK3 (44), Tyro 3 (45), and an Elk-like kinase).
Ten of the kinases were membrane-bound receptors (EGF re-
ceptor, Bek, Axl, Tyro 3, Tyro 10, Eck, Elk-like, Flk, Flt, and
IGF-I receptor), and two were Src family members (Fyn and
Src); neither group would likely be the Ang II-regulated kinase
whose activity is .80% soluble. Of the eight other intracellular
tyrosine kinases (Fer, Abl, Abl-related, Csk-1, FAK, JAK1,
JAK2, and JAK3), all but Csk-1 and Abl-related were ruled out
as the major calcium-dependent kinase in double immunopre-
cipitation experiments similar to those done in Figs. 2 and 3
(data not shown). Csk-1 is not autophosphorylated, and thus
would not be a kinase activity immunoprecipitated with anti-
Tyr(P) antibodies (46). This left the abl-related sequence (47)
(which we have not formally ruled out, but which is not in the
correct molecular weight range). Since a recent report demon-
strated Ang II-dependent JAK2 activation in rat smooth mus-
cle cells (48), we specifically tested for the ability of Ang II and
a known JAK2 stimulus, growth hormone (49), to stimulate
JAK2 autophosphorylation in GN4 cells. Fig. 5 shows that Ang
II failed to increase JAK2 tyrosine phosphorylation at 1, 15, or
30 min, while human growth hormone clearly increases JAK2
tyrosine phosphorylation.
Purification—GN4 cells grown to confluence were treated
with Ang II for 60 s, and cell lysates were harvested by deter-
gent lysis. Lysates were incubated with anti-phosphotyrosine
PT66-agarose, washed, and eluted with phenylphosphate, re-
sulting in a substantial purification with respect to protein.
Multiple Tyr(P) substrates were isolated. This fraction (termed
Tyr(P) elute in Fig. 6) was passed over an ATP-Sepharose
column (ATP linked with a spacer through the g-phosphate),
allowing efficient isolation of ATP-binding Tyr(P) proteins.
Greater than 90% of the silver-staining protein and Tyr(P)
substrate was not adsorbed and was found in the flow-through
fractions of the ATP column.
Fig. 6 (panel A) shows an analysis at the end of a typical
purification using a standard gel polyacrylamide gel. At least
five Tyr(P)-containing proteins adsorbed to the ATP column
(p170, p140, p125, p115–120, and p75) were eluted with 1 mM
ATP and were concentrated by overnight reincubation with
PT66-agarose. This last step was followed by washing and
extraction of the purified proteins in SDS sample buffer (final
Tyr(P) step). The lower band in the 115–120-kDa region corre-
sponded to the most heavily autophosphorylated protein seen
in Fig. 3. A second purification was examined using a gel with
a low bisacrylamide concentration to enhance separation of
phosphoproteins in the 120-kDa region (Fig. 6B). The gel allows
visualization of the 115–120-kDa Tyr(P) protein below the 120-
kDa prestained marker separated from the preponderance of
Tyr(P) substrates above the 120-kDa marker. Most of these did
not adsorb to or elute from the ATP column. This can be seen
even more clearly in Fig. 6C, which shows the results from a
third purification in which the ATP eluate was concentrated
;20-fold using a final Tyr(P) step. Again the low bisacrylamide
gel was used. This third purification was also used to confirm
the specificity of the ATP affinity column by identifying two of
the trace Tyr(P) proteins in final ATP eluate as the EGF re-
ceptor and pp125FAK. The eluate from the ATP affinity resin
was aliquoted into three fractions, which were concentrated by
precipitation with either PT66-agarose (labeled the final Tyr(P)
step), rat EGF receptor polyclonal antiserum, 1382, or the
p125FAK monoclonal 2A7. The PT66 lane was loaded with only
1/25 the sample used in the EGF receptor or p125FAK lanes.
FIG. 4. Lack of complete inhibition of Ang II-dependent tyro-
sine phosphorylation in cells preincubated with cytochalasin D.
GN4 cells were pretreated with 2 mM cytochalasin D for 2 h and then
treated with Ang II for 1 min. Cells were lysed, and lysates were
subjected to 8% SDS-PAGE and transferred to nitrocellulose as de-
scribed under “Experimental Procedures.” Phosphotyrosine immuno-
blotting (PT66) shows the presence of tyrosine phosphorylation in Ang
II-treated cells that is resistant to cytochalasin inhibition (115–130-kDa
region). The tyrosine phosphorylation in the 65–75-kDa region stimu-
lated by Ang II is inhibited by cytochalasin.
FIG. 5. JAK2 is not significantly tyrosine-phosphorylated in
Ang II-treated GN4 cells. GN4 cells were treated with Ang II (AII, 1
mM), growth hormone (GH, 100 ng/ml), or interferon g (IFNg, 500
units/ml) for the indicated times. Cells were lysed and immunoprecipi-
tated with anti-phosphotyrosine (PT66) antibodies. Immune complexes
were subjected to SDS-PAGE, transfer to nitrocellulose, and immuno-
blotting with anti-JAK2 antibody (generously provided by James Ihle,
St. Judes). Growth hormone stimulated JAK2 autophosphorylation,
while Ang II did not. The effect of IFNg was minimal. Lane 1 was
immunoprecipitated with anti-JAK2, showing total immunoprecipi-
table JAK2 from GN4 cells.
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p170 eluted from the ATP column was precipitated by the EGF
receptor antibody. The Tyr(P)-containing protein band that
migrated just above the 120-kDa molecular mass marker on
low bisacrylamide gels was immunoprecipitated by p125FAK
monoclonal. Two separate immunoblots of the concentrated
final Tyr(P) step were performed using the p125FAK mono-
clonal antibody 2A7 or the polyclonal antibody BC-2 (raised
against the p125FAK tyrosine kinase domain, amino acids 311–
701). These confirmed that the band migrating above the 120-
kDa marker on the low bisacrylamide gel was p125FAK; the
substrate migrating below the 120-kDa marker did not react
with either the p125FAK monoclonal or antisera even though
there was greater than 20 times the silver staining protein in
the 115–120-kDa band (data not shown).
Fig. 7 shows that the tyrosine autokinase activity from an
aliquot of the same immune complexes used for the immuno-
blots depicted in Fig. 6C. The auto kinase activity is almost
totally confined to the band running just below the 120-kDa
marker, with an apparent molecular mass of 115–120 kDa. The
EGF receptor immunoprecipitate shows little or no autokinase
activity, and the p125FAK 2A7 immune complex exhibited
barely detectable kinase activity. A reimmunoprecipitation
with PT66 after immunodepleting EGF receptor or p125FAK,
respectively, showed that PT66 could still precipitate the 115–
120-kDa autokinase activity. While the purification yielded
tyrosine-phosphorylated EGF receptor and FAK that bind the
ATP column, their tyrosine kinase activity is minimal either by
virtue of their low abundance (compared to the 115–120-kDa
protein) or due to differential loss of activity. The p140 and p75
substrates were not phosphorylated in vitro in this preparation
under these conditions. Thus, 115–120-kDa protein appears to
be the major kinase from the Ang II-treated cells.
DISCUSSION
Downstream signaling from G-protein-coupled receptors is
extraordinarily diverse as these receptors are involved in some
manner in most physiologic processes. In general, stimulation
of G-protein-coupled receptors results in activation of Ser/Thr
kinases (21, 22). However, in certain cell types, hormones or
agonist lipids that bind to G-protein-coupled receptors stimu-
late tyrosine phophorylation, and sometimes even cell prolifer-
ation. In addition, this subset of hormone G-protein-coupled
receptors can activate the MAP kinase pathway (15, 16, 20,
36–39) and can lead to immediate early gene expression2 (50).
FIG. 6. Purification of a 120-kDa tyrosine kinase activity in GN4 cells by phosphotyrosine and ATP affinity column chromatog-
raphy. Cells were treated with Ang II (1 mM) for 1 min, lysed in detergent buffer, and purified over phosphotyrosine-agarose (PT66) as described
under “Experimental Procedures.” Proteins were eluted from the PT66-agarose with 10 mM phenyl phosphate and passed over a ATP-Sepharose
column, from which they were eluted with 1 mM ATP. The eluates were immunoprecipitated with PT66-agarose at 0 °C and eluted by boiling in
SDS sample buffer. Aliquots were saved at each step for Tyr(P) immunoblot analysis. A, phosphotyrosine immunoblot of a standard 3%/8%
SDS-PAGE gel showing proteins eluted from phosphotyrosine (PT66)-agarose (P-tyr eluate), the proteins not bound by ATP-agarose (ATP flow
thru), the eluate from the ATP-agarose (ATP eluate), and concentration of the ATP eluate by a second phosphotyrosine immunoprecipitation (Final
p-tyr step). B, a second purification was analyzed by phosphotyrosine immunoblotting as in A, but using a gel with a low bisacrylamide ratio
designed to better separate the 120-kDa region phosphoproteins. This panel indicates the presence of two tyrosine phosphorylated proteins just
below the mass of Tyr(P) substrates that are selectively retained by ATP-Sepharose, suggesting that they are ATP-binding proteins. One of these
Tyr(P) proteins migrates just below the 120-kDa marker. C, in a third purification, the fraction eluted from the ATP resin by ATP was aliquoted,
precipitated with either anti-Tyr(P) (PT66), EGF receptor (EGFR(1382)), or p125FAK (Fak(2A7)) antibodies, and run on a gel with low bisacryl-
amide ratio in preparation for Tyr(P) immunoblotting. Twenty-five-fold more immune complex was loaded into the EGFR and p125FAK lanes. The
immunoprecipitates demonstrate that at least two known kinases (EGFR and p125FAK) were purified by sequential Tyr(P) and ATP affinity
chromatography. These two known kinases were present in lower amounts than the major Tyr(P)-containing protein, which migrated just below
the 120-kDa marker.
FIG. 7. Autophosphorylation of Tyr(P) proteins immunopre-
cipitated from fractions eluted from ATP-Sepharose with ATP.
A portion of the purification used for the Tyr(P) immunoblot in Fig. 6C
was used for the following immunoprecipitations and immune complex
kinase assays. Proteins eluted from the ATP resin were immunopre-
cipitated: (i) directly with PT66-agarose (Final tyr-p step), (ii) with EGF
receptor antibody, 1382 (EGFR IP), (iii) following the EGF receptor
precipitation the remaining supernatant was reimmunopreciptated
with PT66-agarose (Final Tyr(P) step-EGFR), (iv) with anti-p125FAK
antibody, 2A7 (FAK IP), or (v) following the 2A7 precipitation the
remaining supernatant was reimmunoprecipitated with PT66-agarose
(Final p-tyr step-FAK). All immune complexes were incubated with
[g-32P]ATP 60 mM (10 mCi) in phosphorylation buffer as described under
“Experimental Procedures.” Following a 1-min incubation, the samples
were boiled in SDS sample buffer, subjected to SDS-PAGE, and auto-
radiographed. The EGF receptor and p125FAK constitute a small frac-
tion of the autophosphorylating kinase activity in the final Tyr(P) step,
the majority of the activity was found in the 115–120-kDa protein.
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In rat liver epithelial cells, Ang II alone not only stimulates
proliferation, it also activates the MAP kinase and JNK kinase
pathways and modifies transcription factor activity as ad-
judged by increased AP-1 binding. The Ang II actions on MAP
kinase and JNK are protein kinase C-independent, as well as
calcium/calmodulin-independent, yet both actions are inhibited
by genistein, implicating the involvement of a tyrosine kinase.2
Activation of JNK in a calcium-dependent, tyrosine kinase-de-
pendent manner has not been observed in other cells (51).
Thus, binding to the Ang II receptor and the resultant bg and
calcium signals may have differential consequences depending
upon the downstream signaling elements expressed in the cell
types under study. The expression of a novel tyrosine kinase
activated in a G-protein- and/or calcium-dependent manner
may allow additional Ang II-dependent actions in some cells,
i.e. Ang II may stimulate multiple pathways in cells in which it
activates more than one tyrosine kinase.
Subcellular fractionation demonstrated that many of the
Tyr(P) substrates and virtually all of the activated tyrosine
kinase in Ang II-treated cells were soluble. Our catalogue of rat
liver epithelial cell tyrosine kinases yielded several intracellu-
lar candidates (p125FAK and the JAKs) as potential calcium-
regulated tyrosine kinases in the 115–130-kDa range. p125FAK
is both tyrosine phosphorylated and minimally activated in
Ang II-treated cells, but it is a minor component of the Ang
II-dependent response (Figs. 2 and 3). The JAK kinases, while
often found in the particulate fraction, presumably non-co-
valently bound to their associated cytokine receptor (52), could
be released from the membrane and activated by a calcium-de-
pendent step. In addition, another group reported that Ang II
activated JAK2 in smooth muscle cells (48), and a second group
showed Ang II stimulation of serum-inducible element binding
(53), often regarded as evidence of JAK pathway activation
(52). We have not seen evidence of increased serum-inducible
element binding in Ang II-treated GN4 cells2, nor do we detect
significant JAK2 tyrosine phosphorylation in an Ang II-treated
rat liver epithlelial cells (Fig. 7). Evidence for JAK2 activation
in smooth muscle cells and its absence in rat liver epithelial
cells confirms the cell type complexity of intracellular tyrosine
kinase signaling.
The p125FAK immunoprecipitation experiments (Figs. 2 and
3) suggested that another tyrosine kinase was activated in Ang
II-treated cells; the kinase purification supports this conclu-
sion. The sharp band of activity seen in immune complexes
(Fig. 3) appears to be the major autophosphorylating kinase
activity isolated by large scale Tyr(P) and ATP affinity chro-
matography (Figs. 6 and 7). After the ATP affinity step, the
p115–120-kDa Tyr(P) autophosphorylating protein is the dom-
inant band on silver-stained gels, and in some preparations, it
is the only band (data not shown). By Tyr(P) immunoblotting,
a much more sensitive technique than silver staining, most
preparations eluted from the ATP resin and concentrated with
PT66-agarose contain varying proportions of five Tyr(P) pro-
teins: p170, p140, p125, p115–120, and p75. The p115–120
band is always dominant. The selectivity of the ATP affinity
step was confirmed by the identity of p170 and p125 as known
tyrosine kinases. The presence of the EGF receptor (p170) was
surprising because even with immunoprecipitation of a 60-mm
GN4 culture dish with anti-EGF receptor antibody, we have
not observed Ang II-dependent EGF receptor phosphorylation.
However, in purifications using 50 150-mm culture dishes,
enough tyrosine-phosphophorylated EGF receptor is present to
be specifically purified by the dual affinity procedure. The
contribution of the EGF receptor and p125FAK to the autoki-
nase activity in the final preparation is dwarfed by the activity
in p115–120-kDa protein (Fig. 7). Since the p115–120-kDa
protein is much more abundant, we cannot speculate on the
specific activities of the putative calcium-regulated tyrosine
kinase (p115–120) and p125FAK. The p115–120-kDa protein
does not immunologically cross-react with either p125FAK
monoclonal 2A7, or a polyclonal raised against the p125FAK
tyrosine kinase domain. This does not preclude the putative
novel kinases’s similarity to p125FAK, but suggests that any
relationship may be distant. Finally, there is little 32P incor-
poration into p140 and p75 at this stage of the purification. We
do not know whether these are low specific activity kinases,
other ATP binding proteins, or Tyr(P) proteins specifically
bound to one of the ATP binding kinases.
In summary, Ang II activates at least two tyrosine kinases in
rat liver epithelial cells, p125FAK and a second activity, which
appears to migrate at p115–120-kDa. In addition, Ang II acti-
vates at least two downstream signaling pathways: the Jun
N-terminal kinase, activated in a calcium- and tyrosine kinase-
dependent manner, and MAP kinases whose activation by Ang
II is less dependent on a calcium signal.2 It will be of interest to
determine whether the Ang II-dependent activation of distinct
tyrosine kinases regulates separate intracellular signaling
cascades.
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